Biopharma companies spend at least 25% of their revenue on research and development (R&D) … but this is a problem for new companies with no revenue to draw from.
Analysts expect expenses for pharmaceutical R&D to top $254 billion by 2026.
Today’s Power Stock helps biopharma companies find capital and rates a perfect 100 on our proprietary system.
By: Matt Clark, Research Analyst
Research and development, or R&D, is the lifeblood of the biopharmaceutical industry.
Biopharma companies spend 25% or more of their revenues on R&D of new drugs and products to help save lives.
Only the semiconductor industry spends more on R&D.
Analysts expect spending to hit $254 billion by 2026 — an 85% increase from 2012.
But startup biopharma companies face a problem: Most don’t have the revenue to reinvest in R&D. That leaves them to look for new capital to fund development.
I’m pleased to tell you about today’s Power Stock, which helps growing biopharma startups.
Privacy Policy The Money & Markets, P.O. Box 8378, Delray Beach, FL 33482.
To ensure that you receive future issues of Money & Markets, please add info@mb.moneyandmarkets.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance.
The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: https://moneyandmarkets.com/contact-us/
Legal Notice: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Money & Markets expressly forbids its writers from having a financial interest in their own securities or commodities recommendations to readers. Such recommendations may be traded, however, by other editors, Money & Markets, its affiliated entities, employees, and agents, but only after waiting 24 hours after an internet broadcast or 72 hours after a publication only circulated through the mail.
(c) 2022 Money & Markets, LLC. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Money & Markets. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 800-684-8471)
Post a Comment
Post a Comment